Ernexa Therapeutics Inc. (ERNA) › Cash & EquivalentsErnexa Therapeutics Inc. (ERNA) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2009-12-31: $3.64M2010-12-31: $3.91M2011-12-31: $1.37M2012-12-31: $2.72M2013-12-31: $5.46M2014-12-31: $7.18M2015-12-31: $3.22M2016-12-31: $5.69M2017-12-31: $3.38M2018-12-31: $2.54M2019-12-31: $3.21M2020-12-31: $777.0K2021-12-31: $16.98M2022-12-31: $11.45M2023-12-31: $7.58M2024-12-31: $1.73M$1.73M2009-12-31Cash & Equivalents (USD)2024-12-31Period endedCash & EquivalentsChange YoYSource filing2024-12-31$1.73M-77.2%2025-03-12Balance as of period end2023-12-31$7.58M-33.8%2025-03-12Balance as of period end2022-12-31$11.45M-32.6%2024-03-14Balance as of period end2021-12-31$16.98M+2086.0%2023-03-20Balance as of period end2020-12-31$777.0K-75.8%2021-03-11Balance as of period end2019-12-31$3.21M+26.5%2021-03-11Balance as of period end2018-12-31$2.54M-24.9%2020-03-19Balance as of period end2017-12-31$3.38M-40.6%2019-03-22Balance as of period end2016-12-31$5.69M+76.4%2018-03-09Balance as of period end2015-12-31$3.22M-55.1%2018-03-09Balance as of period end2014-12-31$7.18M+31.7%2017-03-09Balance as of period end2013-12-31$5.46M+100.5%2016-03-15Balance as of period end2012-12-31$2.72M+98.0%2015-03-27Balance as of period end2011-12-31$1.37M-64.8%2014-03-31Balance as of period end2010-12-31$3.91M+7.4%2013-03-29Balance as of period end2009-12-31$3.64M—2012-03-30Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)